PARP Inhibitors in Oncology
Summary: Since hitting the market in 2015, drugs that target poly (ADP-ribose) polymerase (PARP) have transformed the clinical management of cancers harboring BRCA-mutations. As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. This report covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies. Get Free Sample Report: ...